Barclays analyst Etzer Darout raised the firm’s price target on CytomX Therapeutics (CTMX) to $8 from $6 and keeps an Overweight rating on the shares. The firm believes the company’s upcoming readout in colorectal cancer has “compelling risk-reward.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX: